Abstract 1652P
Background
Obesity amplifies the risk for various cancers, including pancreatic cancer (PC). Due to limited early screening methods, this study seeks to investigate the effects of obesity-related metabolic disorders on PC initiation and offer novel insights into early detection and diagnosis in obese populations.
Methods
Human pancreatic Nestin-expressing ductal cells (HPNE) were cultured with human serum obtained from obese patients and healthy individuals. Transcriptomics, untargeted metabolomics, and joint-pathway analyses were conducted to examine the impacts of obesity-related metabolic disorders on pancreatic carcinogenesis. Multiomics analysis results were validated using cells of varying genetic backgrounds, while their mechanisms and roles in PDAC development were explored in obese transgenic mouse models. Clinical relevance and translational value were also corroborated using public databases and human samples.
Results
Multiomic assessment revealed heightened cytokine signalling and ferroptosis defence in HPNE cells exposed to obesity serum. In vitro tests showed that upregulated interleukin 34 (IL-34) strengthens ferroptosis defence through oxidative stress, while the enhanced ferroptosis defence reciprocally raises IL-34 levels. Our study demonstrated that augmented IL-34 signalling and ferroptosis defence hasten PDAC initiation in diet-induced obese mice by increasing immunosuppressive macrophages infiltration. Public databases revealed a strong correlation between elevated IL-34 and glutathione peroxidase 4 (GPX4) expression in pancreatic tumors vs. normal tissues. Gene signature expression displayed substantial correlations as well. Cohort validation and single-cell analysis suggested a positive association between IL-34 signalling and ferroptosis defence enhancement with PDAC patients' body mass index (BMI).
Conclusions
Obesity elevates IL-34 signalling and ferroptosis defence, thereby promoting PDAC development via macrophage-induced immunosuppression. The observed positive correlations between IL-34 and BMI, as well as GPX4 and BMI in PDAC patients underscore their potential roles in early PC screening among the obese population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This project received funding from the Chinese Academy of Medical Sciences (CAMS) Innovation Fund for Medical Sciences (CIFMS, 2021-I2M-1-002), National High Level Hospital Clinical Research Funding (2022-PUMCH-D-001), National Multidisciplinary Cooperative Diagnosis and Treatment Capacity Building Project for Major Diseases, National Natural Science Foundation of China (NSFC, 81970763), Foundation Project for Young Scientists of NSFC (82102810), the Fellowship of China Postdoctoral Science Foundation (2021M700501), the Postdoctoral ScienceFoundation of Peking Union Medical College Hospital (2022T150067), and the Non-profit Central Research Institute Fund of CAMS (2018PT32014).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1569P - The CODRP model for predicting drug sensitivity in patient-derived 3D gastric cancer cells
Presenter: Dong Woo Lee
Session: Poster session 22
1571P - Exploration of immune and metabolism gene signature for prognosis of esophageal carcinoma and establishment of a combined prediction model
Presenter: Hao Wu
Session: Poster session 22
1572P - Impact of HER2 and PD-L1 co-expression in Claudin18.2 positive resectable gastroesophageal cancers
Presenter: Antonella Cammarota
Session: Poster session 22
1573P - Involved field and elective nodal irradiation presented similar treatment efficiency in concurrent chemoradiation for locally advanced ESCC
Presenter: Baosheng Li
Session: Poster session 22
1575P - Factors associated with uptake of adjuvant nivolumab in a nationwide esophageal cancer patient cohort
Presenter: Rob Verhoeven
Session: Poster session 22
1577P - Prior antibiotic administration disrupts outcomes of PD-1 blockade in advanced gastric cancer by altering gut microbiome and systemic immune response
Presenter: Chang Gon Kim
Session: Poster session 22
1578P - Effect of immune checkpoint inhibitors in metastatic gastric cancer: A real-world evidence study
Presenter: Francesco Puccetti
Session: Poster session 22